HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.

Abstract
Antiplatelet and antithrombotic activity of multiple oral dosing of prasugrel were evaluated in several animal species. Prasugrel's active metabolite concentration-relatedly inhibited in vitro ADP-induced aggregation of rat, rabbit, dog, monkey and human platelets. Oral administration of prasugrel to dogs (0.03-0.3 mg/kg/day) and monkeys (0.1 and 0.3 mg/kg/day) once a day for 14 days resulted in potent, dose-related and cumulative inhibition of ADP-induced platelet aggregation. The inhibitory effects reached a plateau on days 3 to 5 and thereafter were maintained during dosing. Inhibition decreased gradually after cessation of dosing with near full recovery by 7 days after last dose. Antiplatelet and antithrombotic activity of prasugrel and clopidogrel were further examined in rats. Multiple oral dosing of prasugrel (0.3-3 mg/kg/day) to rats resulted in more potent inhibition of platelet aggregation compared to clopidogrel (3-30 mg/kg/day) and ticlopidine (30-300 mg/kg/day). Separate experiments confirmed that platelet inhibition was associated with inhibition of [(3)H]-2-methylthio-ADP binding to rat platelets. In a rat model of electrically-induced arterial thrombosis, prasugrel (0.1-1 mg/kg/day, p.o.) significantly prolonged the time to arterial occlusion and increased the duration of arterial patency. The inhibition of platelet aggregation of prasugrel was about 10 and 300 times more potent than clopidogrel and ticlopidine, respectively. Overall these results show that in several species multiple oral administration of prasugrel results in more potent inhibition of platelet aggregation and thrombus formation than clopidogrel and ticlopidine, and that these effects are mediated by inhibition of platelet ADP receptors.
AuthorsYoichi Niitsu, Atsuhiro Sugidachi, Taketoshi Ogawa, Joseph A Jakubowski, Masami Hashimoto, Takashi Isobe, Ken-Ichi Otsuguro, Fumitoshi Asai
JournalEuropean journal of pharmacology (Eur J Pharmacol) Vol. 579 Issue 1-3 Pg. 276-82 (Jan 28 2008) ISSN: 0014-2999 [Print] Netherlands
PMID17996866 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Piperazines
  • Platelet Aggregation Inhibitors
  • Purinergic P2 Receptor Antagonists
  • Thiophenes
  • Clopidogrel
  • Prasugrel Hydrochloride
  • Ticlopidine
Topics
  • Administration, Oral
  • Adult
  • Animals
  • Clopidogrel
  • Dogs
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Humans
  • In Vitro Techniques
  • Macaca fascicularis
  • Male
  • Middle Aged
  • Piperazines (administration & dosage, pharmacology)
  • Platelet Aggregation (drug effects)
  • Platelet Aggregation Inhibitors (administration & dosage, pharmacology)
  • Prasugrel Hydrochloride
  • Purinergic P2 Receptor Antagonists
  • Rabbits
  • Rats
  • Rats, Sprague-Dawley
  • Species Specificity
  • Thiophenes (administration & dosage, pharmacology)
  • Thrombosis (drug therapy)
  • Ticlopidine (analogs & derivatives, pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: